Clinical Trials Directory

Trials / Completed

CompletedNCT00402194

Treating the Endothelium to Restore Insulin Sensitivity

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
17 (actual)
Sponsor
Indiana University School of Medicine · Academic / Other
Sex
All
Age
20 Years – 55 Years
Healthy volunteers
Accepted

Summary

A study of 12 weeks' treatment with losartan or placebo, to test the hypothesis that RAS inhibition will improve insulin' vascular actions and therefore improve insulin sensitivity in skeletal muscle.

Detailed description

Recent studies suggesting an effect of cardiovascular therapies to prevent diabetes remain unexplained. We hypothesize that these therapies improve vascular endothelial function allowing improved actions of insulin in the vasculature, which comprise a significant portion of insulin's metabolic action. We therefore propose to measure insulin-mediated glucose disposal and insulin-mediated vasodilation before and after 12 weeks' therapy with Losartan (an angiotensin receptor blocker) or placebo, in a randomized design. Subjects will include 28 subjects with impaired glucose tolerance, which is generally accompanied by both insulin resistance and impaired vascular function. With this number of participants we have a 90% chance of showing a statistically significant and clinically meaningful effect of insulin on leg vascular resistance, and an even higher chance of showing a difference in insulin's metabolic effects. Exclusion criteria will include frank hypertension, diabetes, or hypercholesterolemia, and biochemical or other contraindications to losartan therapy. The primary endpoint for statistical analysis will be the invasive measure of insulin-stimulated endothelial function. We anticipate an improvement in both vascular and metabolic measures of insulin action following Losartan therapy but no change from untreated baseline following placebo.

Conditions

Interventions

TypeNameDescription
DRUGLosartanTablet, 100mg, once per day for 3 months

Timeline

Start date
2005-06-01
Primary completion
2011-11-01
Completion
2012-03-01
First posted
2006-11-22
Last updated
2013-09-24
Results posted
2013-09-24

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00402194. Inclusion in this directory is not an endorsement.